Arcus Biosciences (RCUS) Other Non-Current Liabilities (2017 - 2026)

Arcus Biosciences' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $119.0 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 28.31% year-over-year to $119.0 million in Q1 2026; TTM through Mar 2026 was $119.0 million, a 28.31% decrease from a year earlier, with the FY2025 full-year figure at $135.0 million, down 14.01% from the prior year.
• Other Non-Current Liabilities eased to $119.0 million in Q1 2026 per RCUS's latest filing, from $135.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $166.0 million in Q1 2025 and bottomed at $13.9 million in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $140.0 million (2022), against an average of $121.3 million.
• Across the five-year window, Other Non-Current Liabilities soared 945.12% in 2023 and declined 28.31% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $140.0 million in 2022, then grew by 1.43% to $142.0 million in 2023, then rose by 10.56% to $157.0 million in 2024, then fell by 14.01% to $135.0 million in 2025, then declined by 11.85% to $119.0 million in 2026.
• Per Business Quant, the three latest RCUS Other Non-Current Liabilities figures stand at $119.0 million (Q1 2026), $135.0 million (Q4 2025), and $152.0 million (Q3 2025).